Technetium-99m-sestamibi uptake in myeloma.
A number of reports describe how 99mTc-sestamibi detects benign and malignant primary and metastatic tumors. We report abnormal 99mTc-sestamibi uptake in nine sites in a 53-yr-old patient with histologically and biochemically proven IgG kappa-secreting myeloma. The 99mTc-sestamibi study was undertaken for an unrelated hyperparathyroidism.
Adams
B K
BK
Department of Nuclear Medicine, University of Cape Town, South Africa.
Fataar
A
A
Nizami
M A
MA
D005260:Female; D006801:Humans; D006965:Hyperplasia; D007145:Immunoglobulin kappa-Chains / Q000378:metabolism; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging* / Q000276:immunology; D010280:Parathyroid Glands / Q000000981:diagnostic imaging / Q000473:pathology; D011877:Radionuclide Imaging; D017256:Technetium Tc 99m Sestamibi
D007145:Immunoglobulin kappa-Chains; D017256:Technetium Tc 99m Sestamibi